Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA First-Cycle Approval Rate For NMEs Leaps To 50% In 2003

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA’s efforts to increase first-cycle approvals appear to be paying off, with the agency showing a significant improvement in 2003 compared to 2002.

You may also be interested in...



Complete Submissions Are Key To Good Review Management Principles – FDA

As FDA rolls out its Good Review Management Principles – its attempt to improve FDA’s timely review of drug applications through professional best practices – the agency is stressing the importance of sponsors submitting complete applications to facilitate this process.

Early Meetings Aid First-Cycle Approval If Sponsors Act, Consultants Tell FDA

NDA and BLA sponsors contribute to the need for multi-cycle reviews by failing to act on FDA recommendations made during development "milestone" meetings, according to an independent analysis of the agency’s first-cycle review performance.

Average Approval Time Is Slower For Drugs, Faster For Biologics

Average time to approval rose in 2004 to 18.7 months for NMEs, but biologics average was significantly lower at 20.2 months. 2003 averages were 17.1 for drugs, 36.9 for biologics

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS002443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel